MA46365A - Méthodes de traitement de troubles mitochondriaux et métaboliques - Google Patents
Méthodes de traitement de troubles mitochondriaux et métaboliquesInfo
- Publication number
- MA46365A MA46365A MA046365A MA46365A MA46365A MA 46365 A MA46365 A MA 46365A MA 046365 A MA046365 A MA 046365A MA 46365 A MA46365 A MA 46365A MA 46365 A MA46365 A MA 46365A
- Authority
- MA
- Morocco
- Prior art keywords
- mitochondrial
- treatment
- methods
- metabolic disorders
- metabolic
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000012268 mitochondrial disease Diseases 0.000 title 1
- 230000002438 mitochondrial effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401092P | 2016-09-28 | 2016-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46365A true MA46365A (fr) | 2019-08-07 |
Family
ID=61763007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046365A MA46365A (fr) | 2016-09-28 | 2017-09-28 | Méthodes de traitement de troubles mitochondriaux et métaboliques |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190307732A1 (fr) |
| EP (1) | EP3518923A4 (fr) |
| JP (2) | JP2019529474A (fr) |
| KR (2) | KR102475256B1 (fr) |
| CN (1) | CN110022876A (fr) |
| AU (1) | AU2017335902B2 (fr) |
| BR (1) | BR112019006113A2 (fr) |
| CA (1) | CA3038824A1 (fr) |
| CL (1) | CL2019000787A1 (fr) |
| EA (1) | EA201990820A1 (fr) |
| IL (1) | IL265566A (fr) |
| MA (1) | MA46365A (fr) |
| MX (1) | MX389962B (fr) |
| WO (1) | WO2018064405A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470071A1 (fr) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Thérapie contre le cancer du sein fondée sur le statut des récepteurs hormonaux, dans laquelle sont utilisées des nanoparticules comprenant du taxane |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| IL277402B1 (en) * | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| TW202015659A (zh) * | 2018-05-22 | 2020-05-01 | 美商亞伯辛生物科學有限責任公司 | 用於治療肺高血壓之方法及組合物 |
| KR102936433B1 (ko) | 2019-03-19 | 2026-03-09 | 아브락시스 바이오사이언스, 엘엘씨 | 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여 |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| CN111621556A (zh) * | 2019-12-31 | 2020-09-04 | 安徽医科大学第一附属医院 | 一种检测人线粒体atp6基因8993位点基因型的试剂盒及方法 |
| CN111419876A (zh) * | 2020-04-30 | 2020-07-17 | 复旦大学附属中山医院 | 线粒体移植在治疗原发性扩心病中的应用 |
| CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
| CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
| CN114507677B (zh) * | 2022-02-16 | 2023-09-05 | 中国人民解放军空军军医大学 | Ndufs1基因在治疗心梗后心衰中的应用和相关产品 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003259803B2 (en) * | 2002-08-12 | 2007-08-02 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
| EP1853610A1 (fr) * | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | Dérivés de n-phénylbenzamide en tant qu'agents régulant la sirtuine |
| US20090029904A1 (en) * | 2006-07-21 | 2009-01-29 | Sean Oldham | Compositions and methods for treatment of insulin-resistance diseases |
| EP2131821B1 (fr) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticule comprenant de la rapamycine et de l'albumine utilisée comme agent anticancéreux |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| ES2645692T3 (es) * | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| MX2012011155A (es) * | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| KR101970342B1 (ko) * | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| WO2013024467A2 (fr) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Protéines ribosomales mitochondriales en tant que régulateurs du vieillissement |
| RU2015143490A (ru) * | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| AU2014348657A1 (en) * | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
| WO2016134486A1 (fr) * | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Utilisation de canagliflozine et de ses dérivés dans le traitement du cancer |
| WO2017096270A1 (fr) * | 2015-12-03 | 2017-06-08 | The Regents Of The University Of California | Méthodes de traitement de maladies mitochondriales |
| US11249156B2 (en) * | 2016-04-25 | 2022-02-15 | Koninklijke Philips N.V. | Magnetic resonance radiation shield and shielded main magnet |
-
2017
- 2017-09-28 EP EP17857459.6A patent/EP3518923A4/fr active Pending
- 2017-09-28 KR KR1020197011866A patent/KR102475256B1/ko active Active
- 2017-09-28 US US16/336,390 patent/US20190307732A1/en not_active Abandoned
- 2017-09-28 EA EA201990820A patent/EA201990820A1/ru unknown
- 2017-09-28 BR BR112019006113A patent/BR112019006113A2/pt not_active Application Discontinuation
- 2017-09-28 KR KR1020227042293A patent/KR20230003239A/ko not_active Ceased
- 2017-09-28 AU AU2017335902A patent/AU2017335902B2/en not_active Ceased
- 2017-09-28 MA MA046365A patent/MA46365A/fr unknown
- 2017-09-28 JP JP2019516447A patent/JP2019529474A/ja active Pending
- 2017-09-28 CA CA3038824A patent/CA3038824A1/fr active Pending
- 2017-09-28 MX MX2019003397A patent/MX389962B/es unknown
- 2017-09-28 WO PCT/US2017/054149 patent/WO2018064405A1/fr not_active Ceased
- 2017-09-28 CN CN201780072508.4A patent/CN110022876A/zh active Pending
-
2019
- 2019-03-24 IL IL265566A patent/IL265566A/en unknown
- 2019-03-26 CL CL2019000787A patent/CL2019000787A1/es unknown
-
2022
- 2022-09-16 JP JP2022148199A patent/JP2022191238A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3518923A1 (fr) | 2019-08-07 |
| IL265566A (en) | 2019-05-30 |
| KR102475256B1 (ko) | 2022-12-08 |
| KR20230003239A (ko) | 2023-01-05 |
| CA3038824A1 (fr) | 2018-04-05 |
| MX389962B (es) | 2025-03-20 |
| BR112019006113A2 (pt) | 2019-06-18 |
| EA201990820A1 (ru) | 2019-10-31 |
| MX2019003397A (es) | 2019-06-06 |
| US20190307732A1 (en) | 2019-10-10 |
| JP2019529474A (ja) | 2019-10-17 |
| WO2018064405A1 (fr) | 2018-04-05 |
| AU2017335902A1 (en) | 2019-04-18 |
| EP3518923A4 (fr) | 2020-06-17 |
| KR20190060797A (ko) | 2019-06-03 |
| JP2022191238A (ja) | 2022-12-27 |
| CN110022876A (zh) | 2019-07-16 |
| AU2017335902B2 (en) | 2023-08-24 |
| CL2019000787A1 (es) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46365A (fr) | Méthodes de traitement de troubles mitochondriaux et métaboliques | |
| EP3433266A4 (fr) | Méthodes de traitement de troubles mitochondriaux | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3328376A4 (fr) | Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique | |
| IL262608A (en) | Combination treatment of ocular inflammatory disorders and diseases | |
| MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
| EP2948479A4 (fr) | Évaluation et traitement de troubles médiés par la bradykinine | |
| EP3607072A4 (fr) | Compositions et méthodes de traitement de la phénylcétonurie | |
| EP3634442A4 (fr) | Méthodes de traitement et de prévention de maladies | |
| EP3658139A4 (fr) | Méthodes de traitement de maladies hépatiques | |
| MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
| EP3442515A4 (fr) | Préparation liposomale et méthodes de traitement | |
| EP3386295A4 (fr) | Appareil et méthodes d'ostréiculture | |
| EP3500267A4 (fr) | Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs | |
| EP3313417A4 (fr) | Méthodes de traitement de troubles auto-immuns et allo-immuns | |
| MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
| EP3600285A4 (fr) | Compositions topiques et méthodes de traitement | |
| EP3618783A4 (fr) | Dispositifs et méthodes de traitement des paupières | |
| HRP20180337T1 (hr) | Kalcitonin mimetika za liječenje bolesti i poremećaja | |
| EP3347002A4 (fr) | Méthodes de traitement de troubles neurodégénératifs dans une population spécifique de patients | |
| EP2976094A4 (fr) | Méthodes de traitement de troubles métaboliques | |
| EP3331499A4 (fr) | Composition et méthode de traitement de troubles métaboliques | |
| EP3902536A4 (fr) | Compositions et méthodes de traitement de troubles neurodégénératifs | |
| EP3634370A4 (fr) | Traitement des troubles cutanés | |
| EP3634422A4 (fr) | Méthodes de traitement de la leucodystrophie |